Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

made, Elan Shareholders, as opposed to Elan, would be able to reinvest any cash proceeds in other pharmaceutical companies without paying the control premium which Elan may need to pay to acquire control of such companies.

In the event that the Possible Offer is not made, Elan Shareholders will have limited control over what assets Elan might acquire (as shareholder approval may not be required). Royalty Pharma believes that the risks associated with Elan's future acquisition strategy, and the impact of this strategy on earnings visibility, are substantial.

Furthermore, unlike the "unique" dividend policy announced by Elan on March 4, 2013 whereby Elan Shareholders receive only 20 percent of the Tysabri Royalty over time, the Proposal would allow Elan Shareholders to receive what Royalty Pharma believes is full value for their Elan Stock immediately upon the completion of an offer.

Royalty Pharma's perspective on the assets, attributes and liabilities of Elan today is contained below.

Elan's hard assets

Royalty Pharma believes that substantially all of Elan's assets, following the completion of the Tysabri Transaction, will consist only of net cash of US$3.1 billion[1] or US$5.1 per Elan Stock[2] (to which Royalty Pharma does not ascribe a premium) and the Tysabri Royalty, of which Biogen now has full operating control.

Royalty Pharma believes that the Tysabri Royalty is a financial rather than strategic asset and should therefore be valued on the basis of financial metrics (i.e. intrinsic value). As described elsewhere in this announcement, Royalty Pharma has prepared an illustrative calculation, which assumes that the Disposed Tysabri Percentage is between 46 percent and 54 percent. Using the mid-point of the Disposed Tysabri Percentage Range would indicate that the Tysabri Transaction ascribed a value of US$3.25 billion (US$5.4 per Elan Stock) to the residual Tysabri Royalty.

Royalty Pharma further believes
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... Pasteuria Bioscience announced that it has received registration ... Pasteuria usgae . This is a critical step towards ... bacteria prevalent in soil that have long been recognized as ... , "We,re very pleased to receive this EPA registration," ...
... STOCKHOLM, June 8 Diamyd Medical reported today,that the company ... to include children with type 1 diabetes from 10 years,of ... vaccine Diamyd(R). , (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ... conducting two parallel phase III studies, one in,Europe and one ...
... Through One Year , , HERZLIYA, Israel and SKILLMAN, ... U.S. Food and Drug Administration (FDA) approved a labeling supplement ... EVOLENCE(R), a collagen-based dermal filler for the correction of moderate ... , , To view the Multimedia News Release, go ...
Cached Biology Technology:Pasteuria Bioscience Receives EPA Registration for Nematode Control 2Diamyd(R) Phase III Study Approved for Younger Patients in the US 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... the climate warms and sea ice retreats, the North ... of increasingly open water which is predicted to extend ... this century. Storms thus have the potential to create ... new and unpredictable element to the region. , A University ... in the middle of the Arctic Ocean, and detected ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... engineers at Purdue University have developed a new method ... and they are proposing the creation of mobile processing ... fuels. "What,s important is that you can ... chips, switch grass, corn stover, rice husks, wheat straw ...
... tract is a teeming mass of hundreds of types of ... help us digest food and keep bad bacteria in check. ... receptor is a key player amid the gut bacteria ... helping to govern their activity, responding to their cues, and ...
... calling on policymakers to encourage the transition from coal-based electricity ... carbon tax. Such a mechanism would help limit carbon ... Change Conference in Copenhagen last December, the United States pledged ... by 17 percent by 2020. Dagobert Brito, the ...
Cached Biology News:New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 2Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 3Researchers calculate the cost of CO2 emissions, call for carbon tax 2
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: D H 100 ...
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
... 10.0 kb Autographa californica (AcNPV) polyhedrin locus-based ... polyhedrin promoter and two AcNPV p10 promoters. ... Sma I cloning site, followed by polyhedrin ... polyhedrin promoter has been inserted containing Xba ...
Biology Products: